Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 1-2/2022

09.04.2021 | short report

Psoas muscle index at the time of diagnosis might reflect the prognosis of classical Hodgkinʼs lymphoma patients

verfasst von: MD PhD Marko Lucijanić, Renata Huzjan Korunić, Marija Ivić, Amina Fazlić Džankić, Željko Jonjić, Zdravko Mitrović, Željko Prka, Mario Piršić, Ozren Jakšić, Petar Gaćina, Josipa Vlasac Glasnović, Vlatko Pejša

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

We retrospectively investigated clinical and prognostic significance of psoas muscle index (PMI) calculated as total psoas muscle area at L3 vertebra level obtained from baseline computed tomography (CT) scans in 49 newly diagnosed classical Hodgkinʼs lymphoma (cHL) patients prior to specific treatment. Median PMI was 572.5 mm2/m2 and was significantly higher in males (P < 0.001), patients with higher body mass index (BMI, P < 0.001), absence of extranodal disease (P = 0.037), higher absolute lymphocyte count (P = 0.037), higher hemoglobin (P = 0.010) and lower lactate dehydrogenase (LDH, P = 0.050). There were no significant associations with age, disease subtype, presence of constitutional symptoms, Ann Arbor disease stage, presence of advanced disease or international prognostic score. Patients with lower PMI had significantly worse PFS (hazard ratio [HR] 4.91; P = 0.009). This phenomenon persisted in the multivariate model (HR = 5.09; P = 0.042) adjusted for International Prognostic Score (IPS) and chemotherapy type.
Literatur
1.
Zurück zum Zitat Connors JM, Cozen W, Steidl C, et al. Hodgkin lymphoma. Nat Rev Dis Primers. 2020;6(1):61. CrossRef Connors JM, Cozen W, Steidl C, et al. Hodgkin lymphoma. Nat Rev Dis Primers. 2020;6(1):61. CrossRef
2.
Zurück zum Zitat Cirillo M, Borchmann S. An update on disease biomarkers for Hodgkin lymphoma. Expert Rev Hematol. 2020;13(5):481–8. CrossRef Cirillo M, Borchmann S. An update on disease biomarkers for Hodgkin lymphoma. Expert Rev Hematol. 2020;13(5):481–8. CrossRef
3.
Zurück zum Zitat Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160–8. CrossRef Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160–8. CrossRef
5.
Zurück zum Zitat Lucijanic M, Galusic D, Soric E, et al. Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. Ann Hematol. 2021;100(4):1105-1106. CrossRef Lucijanic M, Galusic D, Soric E, et al. Ruxolitinib treatment improves muscle mass in patients with myelofibrosis. Ann Hematol. 2021;100(4):1105-1106. CrossRef
Metadaten
Titel
Psoas muscle index at the time of diagnosis might reflect the prognosis of classical Hodgkinʼs lymphoma patients
verfasst von
MD PhD Marko Lucijanić
Renata Huzjan Korunić
Marija Ivić
Amina Fazlić Džankić
Željko Jonjić
Zdravko Mitrović
Željko Prka
Mario Piršić
Ozren Jakšić
Petar Gaćina
Josipa Vlasac Glasnović
Vlatko Pejša
Publikationsdatum
09.04.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 1-2/2022
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01850-x